SEARCH BY
| Category | Company |
|---|---|
| Founded | 1935 |
| Sector | Life Science |
| Employees | 30,313 |
| Revenue | 271.5B INR (2025) |
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. Cipla was founded in 1935 and is based in Mumbai, Maharashtra.
| DEAL STATS | # |
|---|---|
| Overall | 6 of 6 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Stake Purchase M&A Deals | 1 of 1 |
| Country: India M&A | 1 of 1 |
| Year: 2022 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-07-24 |
ZEMDRI
San Francisco, California, United States ZEMDRI (Plazomicin) is a once-daily novel intravenous (IV) aminoglycoside for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, in adults who are unresponsive to currently available treatment options. ZEMDRI™ was approved by the United States Food & Drug Administration (USFDA) in June 2018 and was launched in the same year, with patent protection expected to continue until 2031 or 2032. |
Buy | - |
